About Entrez
Text Version
Entrez PubMed
Overview
Help | FAQ
Tutorials
New/Noteworthy
E-Utilities
PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI
Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Limits: **Publication Date to 2003/11/13, Review**

- Search History will be lost after eight hours of inactivity.
- Search numbers may not be continuous; all searches are represented.
- To save search indefinitely, click query # and select Save in My NCBI.
- To combine searches use #search, e.g., #2 AND #3 or click query # for more options.

Search	Most Recent Queries	Time	Result
#19	Search **#4 and (body fluid) or (bodily fluid)** Limits: **Publication Date to 2003/11/13, Review**	10:05:00	21
#16	Search **#4 and (body fluid) or (bodily fluid)** Limits: **Publication Date to 2003/11/13**	10:04:41	94
#18	Search **#4 and (body fluid) or (bodily fluid) and pool** Limits: **Publication Date to 2003/11/13**	10:04:32	0
#17	Search **#4 and (body fluid) or (bodily fluid) and pooled** Limits: **Publication Date to 2003/11/13**	10:04:22	0
#14	Search **autoantibody and screening and hanash** Limits: **Publication Date to 2003/11/13**	10:00:05	3
#13	Search **hanash and autoantibody and screening** Limits: **Publication Date to 2003/11/13, Review**	09:58:09	1
#12	Search **hanash and autoantibody and screeening** Limits: **Publication Date to 2003/11/13, Review**	09:58:04	0
#10	Search **(ras family)** Limits: **Publication Date to 2003/11/13, Review**	09:28:31	486
#9	Search **ras family** Limits: **Publication Date to 2003/11/13, Review**	09:27:57	486
#5	Search **(autoantibody and ras and (cancer or tumor or carcinoma or malignancy))** Limits: **Publication Date to 2003/11/13**	09:04:51	3
#4	Search **(autoantibody and detection and immunoassay and (cancer or tumor or carcinoma or malignancy))** Limits: **Publication Date to 2003/11/13**	09:04:16	148
#3	Search **(autoantibody and immunoassay and (cancer or tumor or carcinoma or malignancy))** Limits: **Publication Date to 2003/11/13**	09:03:44	808
#2	Search **autoantibody and immunoassay and (cancer or tumor or carcinoma or malignancy)** Limits: **Publication Date to 2003/11/13**	09:03:20	808
#1	Search **autoantibody and immunoassay and ras and**	09:03:11	0

(cancer or tumor or carcinoma or malignancy)
Limits: **Publication Date to 2003/11/13**

Clear History

Mar 19 2007 07 18 03

WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Wednesday, March 28, 2007

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ	
☐	L12	L11 and tumor protein or antigen	169426
☐	L11	L10 and immunoassay	15
☐	L10	L9 and autoantibody	21
☐	L9	(hanash samir)	33
☐	L8	(L5 and hanash)	0
☐	L7	(L5 and (bodily fluid) or (body fluid))	91690
☐	L6	L5 and (bodily fluid) or (body fluid)	91690
☐	L5	L2 and immunoassay and (pooled)	342
☐	L4	(L2 and (tumor-associated antigen) or (tumor marker))	6033
☐	L3	L2 and (tumor-associated antigen) or (tumor marker)	6033
☐	L2	(L1 and ras)	648
☐	L1	(autoantibody and detection and (cancer or carcinoma or malignancy or tumor or tumuor) and immunoassay)	1984

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTALAB1643

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 4	DEC 18	CA/CAplus patent kind codes updated
NEWS 5	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 6	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS 7	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS 8	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 9	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 10	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 11	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 12	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 13	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 14	JAN 29	PHAR reloaded with new search and display fields
NEWS 15	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 17	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 18	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 19	FEB 26	MEDLINE reloaded with enhancements
NEWS 20	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS 21	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 22	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 23	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 24	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 25	MAR 16	CASREACT coverage extended
NEWS 26	MAR 20	MARPAT now updated daily
NEWS 27	MAR 22	LWPI reloaded

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:12:55 ON 28 MAR 2007

=> file caplus, bioeng, biotechno, biotechds, esbiobase
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 11:13:30 ON 28 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOENG' ENTERED AT 11:13:30 ON 28 MAR 2007
COPYRIGHT (C) 2007 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHNO' ENTERED AT 11:13:30 ON 28 MAR 2007
COPYRIGHT (C) 2007 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOTECHDS' ENTERED AT 11:13:30 ON 28 MAR 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'ESBIOBASE' ENTERED AT 11:13:30 ON 28 MAR 2007
COPYRIGHT (C) 2007 Elsevier Science B.V., Amsterdam. All rights reserved.

=> s (ras autoantibody) and (cancer or tumor or tumuor or carcinoma or malignancy)
L1 0 (RAS AUTOANTIBODY) AND (CANCER OR TUMOR OR TUMUOR OR CARCINOMA OR MALIGNANCY)

=> s (ras and autoantibody) and (cancer or tumor or tumuot or carcinoma or malignancy)
L2 28 (RAS AND AUTOANTIBODY) AND (CANCER OR TUMOR OR TUMUOT OR CARCINOMA OR MALIGNANCY)

=> duplicate remove L2
DUPLICATE PREFERENCE IS 'CAPLUS, BIOTECHNO, BIOTECHDS, ESBIOBASE'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L2
L3 24 DUPLICATE REMOVE L2 (4 DUPLICATES REMOVED)

=> s (L3 and immunoassay)
L4 7 (L3 AND IMMUNOASSAY)

=> duplicate remove l4
PROCESSING COMPLETED FOR L4
L5 7 DUPLICATE REMOVE L4 (0 DUPLICATES REMOVED)

=> d l5 bib abs 1-7

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:61138 CAPLUS
DN 146:158778
TI Diagnostic method for brain damage-related disorders
IN Hochstrasser, Denis Francois; Sanchez, Jean-Charles
PA Universite de Geneve, Switz.; Lucas, Brian
SO PCT Int. Appl., 99pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007007129	A2	20070118	WO 2006-GB50207	20060714
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	GB 2428240	A	20070124	GB 2005-14435	20050714
PRAI	GB 2005-14435	A	20050714		

AB A brain damage-related disorder is diagnosed in a subject by detecting at least one polypeptide, or a variant or mutant thereof, in a sample of body fluid taken from the subject, wherein the polypeptide is one for which the level is either increased or decreased in cerebrospinal fluid from deceased patients compared to cerebrospinal fluid from healthy donors.

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1253103 CAPLUS
DN 146:26329
TI Improved immunoassay methods
IN Robertson, John Forsyth Russell; Barnes, Tony; Murray, Andrea; Chapman, Caroline
PA ONC-Immune Ltd., UK
SO PCT Int. Appl., 68pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006126008	A2	20061130	WO 2006-GB1944	20060526
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	GB 2426581	A	20061129	GB 2005-10943	20050527
PRAI	GB 2005-10943	A	20050527		
	US 2005-685422P	P	20050527		

AB The invention relates to a method of detecting a disease state or disease susceptibility in a mammalian subject which comprises detecting an antibody in a test sample comprising a bodily fluid from said mammalian subject wherein said antibody is a biol. marker of a disease state or disease susceptibility, the method comprising: (a) contacting said test sample with a plurality of different amts. of an antigen specific for said antibody, (b) detecting the amount of specific binding between said antibody and said antigen, (c) plotting or calculating a curve of the amount of said specific binding vs. the amount of antigen for each amount of antigen used in step (a) and (d) determining the presence or absence of said disease state or disease susceptibility based upon the amount of specific binding between said antibody and said antigen at each different antigen concentration used. The

disease most detected is cancer.

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1176717 CAPLUS
DN 145:487648
TI Cancer diagnosis by serum antibody profiling
IN Liu, Brian C. S.; Qin, Shuzhen; Ehrlich, Joshua R.
PA The Brigham and Women's Hospital, Inc., USA
SO PCT Int. Appl., 48pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006119155	A2	20061109	WO 2006-US16543	20060501

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2005-676301P	P	20050502	
US 2005-750825P	P	20051216	

AB The invention is directed to a microarray assay procedure that can be used for profiling the antibodies present in serum, plasma or blood. The assay may be used to identify antibodies and antigens that are characteristic of particular diseases or conditions. In addition, the invention includes specific antigens that are associated with prostate cancer, progressive benign prostate hyperplasia (BPH) and ovarian cancer
.

L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1242445 CAPLUS
DN 146:6312
TI Antigen titration immunoassay for detection of autoantibodies
IN Robertson, John Forsyth Russell; Barnes, Tony; Murray, Andrea; Chapman, Caroline
PA ONC-Immune Limited, UK
SO Brit. UK Pat. Appl., 56pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI GB 2426581	A	20061129	GB 2005-10943	20050527
WO 2006126008	A2	20061130	WO 2006-GB1944	20060526

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI GB 2005-10943 A 20050527
US 2005-685422P P 20050527

AB The authors disclose a method of detecting an antibody in a bodily fluid wherein the antibody is a biol. marker of a disease state or disease susceptibility. The method comprises: (a) contacting the test sample with a plurality of different amts. of an antigen specific for the antibody, (b) detecting the amount of specific binding between the antibody and the antigen, and (c) plotting or calculating a curve of the amount of the specific binding vs. the amount of antigen for each amount of antigen used in step (a). In one example, using tumor antigen titration, the authors detected autoantibodies against p53, c-Myc, NY-ESO-1, and BRCA2 in women with in situ ductal carcinoma of the breast.

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:405702 CAPLUS
DN 140:390282
TI Method of detection of tumor-associated autoantibodies
IN Graves, Catherine Rosamund Louise; Robertson, John Forsyth Russell
PA The University of Nottingham, UK
SO Brit. UK Pat. Appl., 66 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2395270	A	20040519	GB 2002-26622	20021114
	GB 2395270	B	20060816		
	GB 2424070	A	20060913	GB 2006-4694	20021114
	GB 2424273	A	20060920	GB 2006-4693	20021114
	CA 2545930	A1	20040527	CA 2003-2545930	20031113
	WO 2004044590	A1	20040527	WO 2003-GB4950	20031113
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003282245	A1	20040603	AU 2003-282245	20031113
	EP 1563307	A1	20050817	EP 2003-773863	20031113
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006506612	T	20060223	JP 2004-550841	20031113
	US 2006094069	A1	20060504	US 2005-534773	20050513
	IN 2005DN02050	A	20070119	IN 2005-DN2050	20050513
PRAI	GB 2002-26622	A3	20021114		
	WO 2003-GB4950	W	20031113		

AB An immunoassay for detecting cancer-associated anti-tumor autoantibodies comprising contacting a sample with a tumor marker protein. The tumor marker protein is prepared from the bodily fluid, excretion, or derived from a body cavity or space in which a tumor is or was associated, or one or more cancer patients. The method can be used in the diagnosis of cancer. In an alternative embodiment there is disclosed methods for isolating tumor markers from bodily fluids collected from a

body cavity or space, and another embodiment relates to the preparation of tumor marker proteins from an excretion.

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:402103 CAPLUS
DN 133:40237
TI Cancer detection method and reagents using autoantibodies produced by immortalized monocytes
IN Robertson, John Russell; Graves, Catherine Rosamund Louise; Price, Michael Rawling
PA The University of Nottingham, UK
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000034787	A1	20000615	WO 1999-GB4182	19991210
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2354702	A1	20000615	CA 1999-2354702	19991210
	EP 1137943	A1	20011004	EP 1999-959578	19991210
	EP 1137943	B1	20060329		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
	JP 2002532686	T	20021002	JP 2000-587190	19991210
	AT 322014	T	20060415	AT 1999-959578	19991210
	ES 2257087	T3	20060716	ES 1999-959578	19991210
	PT 1137943	T	20060831	PT 1999-959578	19991210
PRAI	GB 1998-27228	A	19981210		
	WO 1999-GB4182	W	19991210		

AB Sensitive and specific methods are provided for use in detecting the presence of cancer marker proteins in the body fluids of a mammal. Also provided are autoantibodies for use in these methods, and immortalized cells which are a source of the autoantibodies. Serum samples were assayed by ELISA using immobilized autoantibodies produced by B lymphocytes derived from patients with breast cancer. The assay had high sensitivity for cancer-associated forms of MUC1 protein.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:737073 CAPLUS
DN 131:350237
TI Detection of antibody response to tumor markers for diagnostic and prognostic assessment of cancer
IN Robertson, John Forsyth Russell; Graves, Catherine Rosamund Louise; Price, Michael Rawling
PA The University of Nottingham, UK
SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9958978	A2	19991118	WO 1999-GB1479	19990511
	WO 9958978	A3	20000120		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9938388	A	19991129	AU 1999-38388	19990511
	EP 1078264	A2	20010228	EP 1999-921014	19990511
	EP 1078264	B1	20051228		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
	AT 314651	T	20060115	AT 1999-921014	19990511
	PT 1078264	T	20060531	PT 1999-921014	19990511
	ES 2257048	T3	20060716	ES 1999-921014	19990511
	EP 1710253	A2	20061011	EP 2005-28131	19990511
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	EP 1731619	A2	20061213	EP 2005-28132	19990511
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, AL, LT, LV, MK, RO, SI				
PRAI	GB 1998-10040	A	19980511		
	EP 1999-921014	A3	19990511		
	WO 1999-GB1479	W	19990511		

AB The authors disclose the determination of the humoral immune response to circulating tumor marker proteins. The presence of complexes between the tumor marker antigens and any autoantibodies to the antigens present in a sample are detected and provide an assessment of the presence of cancer, its reoccurrence after treatment, and prognosis. In one example, antibodies to MUC-1, c-erbB2, c-myc, and p53 were shown to be indicative not only of cancer onset but also metastatic reoccurrence.

Welcome to DialogClassic Web(tm)

```
 Dialog level 05.17.01D
Last logoff:  15mar07 14:37:33
Logon file1 28mar07 10:21:21
         *** ANNOUNCEMENTS ***
                    ***
NEW FILES RELEASED
***BIOSIS Previews Archive (File 552)
***BIOSIS Previews 1969-2007 (File 525)
***Engineering Index Backfile (File 988)
***Trademarkscan - South Korea (File 655)

RESUMED UPDATING
***File 141, Reader's Guide Abstracts
                    ***
RELOADS COMPLETED
***File 5, BIOSIS Previews - archival data added
***Files 340, 341 & 942, CLAIMS/U.S. Patents - 2006 reload now online
                               ***
DATABASES REMOVED

Chemical Structure Searching now available in Prous Science Drug
Data Report (F452), Prous Science Drugs of the Future (F453),
IMS R&D Focus (F445/955), Pharmaprojects (F128/928), Beilstein
Facts (F390), Derwent Chemistry Resource (F355) and Index Chemicus
(File 302).                        ***
 >>>For the latest news about Dialog products, services, content<<<
 >>>and events, please visit What's New from Dialog at <<<
 >>>http://www.dialog.com/whatsnew/.  You can find news about<<<
 >>>a specific database by entering HELP NEWS <file number>.<<<
 * * *

File   1:ERIC 1965-2007/Feb
       (c) format only 2007 Dialog

      Set  Items  Description
      ---  -----  -----------
Cost is in DialUnits
?

B 155, 159, 10. 203, 35, 5, 467, 73, 434, 34
>>>"10." is not a valid category or service name
       28mar07 10:21:53 User290558 Session D101.1
            $1.07    0.307 DialUnits File1
     $1.07  Estimated cost File1
     $0.14  INTERNET
     $1.21  Estimated cost this search
     $1.21  Estimated total session cost   0.307 DialUnits

SYSTEM:OS  - DIALOG OneSearch
  File 155:MEDLINE(R) 1950-2007/Mar 26
         (c) format only 2007 Dialog
  File 159:Cancerlit 1975-2002/Oct
         (c) format only 2002 Dialog
 *File 159: Cancerlit is no longer updating.
Please see HELP NEWS159.
  File 203:AGRIS 1974-2007/Jan
        Dist by NAL, Intl Copr. All rights reserved
  File  35:Dissertation Abs Online 1861-2007/Feb
         (c) 2007 ProQuest Info&Learning
```

```
  File   5:Biosis Previews(R) 1926-2007/Mar W4
         (c) 2007 The Thomson Corporation
 *File   5: BIOSIS has been enhanced with archival data. Please see
HELP NEWS 5 for information.
  File 467:ExtraMED(tm) 2000/Dec
         (c) 2001 Informania Ltd.
  File  73:EMBASE 1974-2007/Mar 28
         (c) 2007 Elsevier B.V.
  File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
         (c) 2006 The Thomson Corp
  File  34:SciSearch(R) Cited Ref Sci 1990-2007/Mar W3
         (c) 2007 The Thomson Corp

      Set  Items  Description
      ---  -----  -----------
?

S (RAS (W) AUTOANTIBODY) AND (CANCER OR CARCINOMA OR TUMOR OR TUMUOR OR MALIGNANCY)
          185950  RAS
           58863  AUTOANTIBODY
               0  RAS(W)AUTOANTIBODY
         3656021  CANCER
         1818739  CARCINOMA
         3444615  TUMOR
              57  TUMUOR
          246644  MALIGNANCY
      S1       0  (RAS (W) AUTOANTIBODY) AND (CANCER OR CARCINOMA OR TUMOR
                  OR TUMUOR OR MALIGNANCY)
?

S (RAS AND AUTOANTIBODY) AND (CANCER OR CARCINOMA OR TUMOR OR TUMUOR OR MALIGNANCY)
          185950  RAS
           58863  AUTOANTIBODY
         3656021  CANCER
         1818739  CARCINOMA
         3444615  TUMOR
              57  TUMUOR
          246644  MALIGNANCY
      S2      21  (RAS AND AUTOANTIBODY) AND (CANCER OR CARCINOMA OR TUMOR
                  OR TUMUOR OR MALIGNANCY)
?

RD S2
      S3      19  RD S2  (unique items)
?

TYPE S3/FULL/1-19

  3/9/1     (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2007 Dialog. All rts. reserv.

09249851   PMID: 1376057
 Autoantibody-mediated regulation of tumor growth.
  Cahalon L; Korem S; Gonen B; Puri J; Smorodinsky N I; Witz I P
  Department of Cell Research and Immunology, George S. Wise Faculty of
Life Sciences, Tel Aviv University, Israel.
  Annals of the New York Academy of Sciences (UNITED STATES)   May 4 1992,
 651  p393-408,  ISSN 0077-8923--Print   Journal Code: 7506858
  Publishing Model Print
```

Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed
Subfile: INDEX MEDICUS
Descriptors: *Antibodies, Monoclonal--immunology--IM; *Antigens, CD --immunology--IM; *Autoantibodies--immunology--IM; *B-Lymphocyte Subsets --immunology--IM; *Neoplasms, Experimental--immunology--IM; 3T3 Cells; Animals; Antigens, CD5; Cell Line, Transformed; Flow Cytometry; Genes, ras; Immunoglobulin Idiotypes--immunology--IM; Interleukin-2--biosynthesis--BI; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Neoplasms, Experimental --pathology--PA; Polyomavirus--genetics--GE; Research Support, Non-U.S. Gov't; Spleen--immunology--IM; T-Lymphocytes--immunology--IM
CAS Registry No.: 0 (Antibodies, Monoclonal); 0 (Antigens, CD); 0 (Antigens, CD5); 0 (Autoantibodies); 0 (Immunoglobulin Idiotypes); 0 (Interleukin-2)
Gene Symbol: c-Ha-ras
Record Date Created: 19920709
Record Date Completed: 19920709

3/9/2 (Item 1 from file: 35)
DIALOG(R)File 35:Dissertation Abs Online

01662424 ORDER NO: AAD99-01523
SELF DETERMINATION: STUDIES OF POSITIVE AND NEGATIVE SIGNALING IN B LYMPHOCYTES (AUTOIMMUNITY)
Author: HEALY, JAMES IRVIN
Degree: PH.D.
Year: 1998
Corporate Source/Institution: STANFORD UNIVERSITY (0212)
Adviser: CHRISTOPHER C. GOODNOW
Source: VOLUME 59/08-B OF DISSERTATION ABSTRACTS INTERNATIONAL. PAGE 4001. 182 PAGES
Descriptors: HEALTH SCIENCES, IMMUNOLOGY ; BIOLOGY, MOLECULAR
Descriptor Codes: 0982; 0307

The immune system brings destructive power to bear on invading pathogens and cancer cells without harming normal host tissue. The mechanisms that underly this discriminatory capability are unknown. Three potential models could explain how selective responses to antigen receptor ligation are achieved. The lymphocyte antigen receptor could either function like (1) a rheostat and alter the gain on all signaling pathways, (2) a switch board which can engage selected pathways independently or (3) an ignition switch that always triggers the same signals but the nucleus decodes them differently.

Biochemical, genetic and pharmacologic analysis of signaling and cellular responses in self reactive B cells has revealed that the B cell antigen receptor can function like a switch board and selectively trigger different signaling pathways and cell fates. Specifically, self antigen activates the ERK pathway and triggers low level calcium oscillations which translocate the transcription factor NFAT to the nucleus. Additional signals such as NFκB and JNK-1, while activated by foreign antigen, are not triggered by self antigen. Differences in the magnitude of the calcium response in naive and tolerant lymphocytes contributes to differential signaling as NFAT requires persistent, low level calcium but both NFκB and JNK require much higher calcium levels.

The activation of the ras/ERK pathway in tolerant cells appears to prevent autoantibody formation by inducing a global block in

differentiation which prevents upregulation of Syndecan-1, J chain and the plasma cell transcription factor BLIMP-1 and prevents down regulation of CD72 and the homeobox gene Pax5. Pharmacological manipulation of the signaling pathways and regulatory genes described here should allow therapeutic control of the immune system to treat immunodeficiency, autoimmunity, infectious disease and cancer.

3/9/3 (Item 2 from file: 35)
DIALOG(R)File 35:Dissertation Abs Online

01623790 ORDER NO: AAD98-19254
CONTROL OF B LYMPHOCYTE DEVELOPMENT BY RAS AND RAF (P21(RAS))
Author: IRITANI, BRIAN MASAO
Degree: PH.D.
Year: 1997
Corporate Source/Institution: UNIVERSITY OF WASHINGTON (0250)
Chairperson: ROGER M. PERLMUTTER
Source: VOLUME 58/12-B OF DISSERTATION ABSTRACTS INTERNATIONAL.
PAGE 6476. 104 PAGES
Descriptors: HEALTH SCIENCES, IMMUNOLOGY ; BIOLOGY, CELL
Descriptor Codes: 0982; 0379

Many immunodeficiency and autoimmune diseases result from altered function of intracellular signaling proteins that normally control the development and expansion of lymphocytes. Moreover, dysregulation of these intracellular messengers may contribute to the multi-step process leading to the development of cancer. The low molecular weight G-protein p21$\sp{ras}$ is one important oncoprotein that is known to regulate the differentiation and expansion of many cell types including monocytes and T lymphocytes. The broad objective of this dissertation was to develop a whole animal system for dissecting the role of p21$\sp{ras}$ and potential downstream mediators in the differentiation and expansion of B lymphocytes. Specifically, we sought to: (i) Achieve specific disruption of p21$\sp{ras}$ function in B lymphocytes during lymphopoiesis, (ii) Define the developmental stage(s) where p21$\sp{ras}$-directed signaling is necessary for normal B lymphopoiesis, and (iii) Identify potential downstream mediators (pathways) that may direct this signal to the nucleus. The study of p21$\sp{ras}$ function by gene disruption in vivo is problematic because of its ubiquitous expression, and the existence of multiple, potentially redundant isoforms. Therefore, we generated transgenic mice which express a dominant-negative form of Ras in B lymphocyte progenitors, using a novel transcriptional element consisting of the Eμ enhancer and the lck proximal promoter. Expression of dominant-negative Ras arrested B cell development at a very early stage near the point of commitment to the B lymphocyte lineage. An activated form of Raf, a normal target of Ras regulation, expressed in the same experimental system could both drive the maturation of normal pro-B cells and rescue development of progenitors expressing dominant-negative Ras. Additionally, activated Raf could rescue development of both B and T cell progenitors, in the absence of formation of antigen receptors. Hence, p21$\sp{ras}$ normally regulates the development of B lymphocytes at two developmental control points, by a mechanism that appears to involve activation of the serine/threonine kinase Raf. Results of these studies may lead to the synthesis of drugs that can stimulate the development of lymphocytes in immunodeficient individuals, or prevent the development of autoantibody-producing cells during autoimmune disease.

3/9/4 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

16559016 BIOSIS NO.: 200200152527
Myelodysplastic Syndrome with early presentation of refractory monolineage cytopenia. With report of 13 cases
AUTHOR: Chen Shuchang (Reprint); Yu Yanfang (Reprint); Li Shulan (Reprint); Liang Wentong (Reprint); Wang Yuzhou (Reprint); Ge Changwen (Reprint); Feng Sufang (Reprint); Liu Haili (Reprint)
AUTHOR ADDRESS: Department of Hematology, Peking Union Medical College Hospital, Beijing, China**China
JOURNAL: Blood 98 (11 Part 2): p270b November 16, 2001 2001
MEDIUM: print
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 2 Orlando, Florida, USA December 07-11, 2001; 20011207
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: To find the relationship between Myelodysplastic Syndrome (MDS) and refractory monolineage cytopenia. Thirteen cases of MDS with early presentation of monolineage refractory cytopenia were analyzed retrospectively. The results were as follows: 1. The percentage of 13 cases were 0.059 of the total 219 MDS patients in the past 10 years. 2. The median time of patients with monlineage cytopenia was 48.5+-55.3 months. The median times from monolineage cytopenia to MDS diagnosed for patients with neutropenia erythrocytopenia and thrombocytopenia were 12.5+-9.05, 53.8+-54.6, 59.2+-65.5 months respectively. 3. The common characteristics of 13 cases were as follows: A. The macrocytic erythrocytes in peripheral blood and the percentage of intermediate and late erythroblast in bone marrow were increased. B. Occasionally few cells with dysplasia could be found. C. All patients with erythrocytopenia and thrombocytopenia changed to RA and RAS while the most of patients with neutropenia changed to RAEB subtype. D. Autoantibody could be found in part of the patients. It is suggested that some of monolineage refractory cytopenia patients are the early state of MDS.

DESCRIPTORS:
MAJOR CONCEPTS: Blood and Lymphatics--Transport and Circulation; Immune System--Chemical Coordination and Homeostasis; Tumor Biology
BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia
ORGANISMS: human (Hominidae)--patient
ORGANISMS: PARTS ETC: blood--blood and lymphatics; bone marrow--blood and lymphatics, immune system; erythroblast--blood and lymphatics; macrocytic erythrocyte--blood and lymphatics
COMMON TAXONOMIC TERMS: Animals; Chordates; Humans; Mammals; Primates; Vertebrates
DISEASES: dysplasia--disease-miscellaneous; erythrocytopenia--blood and lymphatic disease; myelodysplastic syndrome--blood and lymphatic disease, immune system disease, neoplastic disease, complications, diagnosis, symptom; neutropenia--blood and lymphatic disease; refractory monolineage cytopenia--blood and lymphatic disease, diagnosis; thrombocytopenia--blood and lymphatic disease
MESH TERMS: Myelodysplastic Syndromes (MeSH); Neutropenia (MeSH); Thrombocytopenia (MeSH)

MISCELLANEOUS TERMS: Meeting Abstract; Meeting Abstract
CONCEPT CODES:
00520 General biology - Symposia, transactions and proceedings
02506 Cytology - Animal
02508 Cytology - Human
15002 Blood - Blood and lymph studies
15004 Blood - Blood cell studies
15006 Blood - Blood, lymphatic and reticuloendothelial pathologies
24001 Neoplasms - Diagnostic methods
24003 Neoplasms - Immunology
24004 Neoplasms - Pathology, clinical aspects and systemic effects
24010 Neoplasms - Blood and reticuloendothelial neoplasms
34502 Immunology - General and methods
34508 Immunology - Immunopathology, tissue immunology
BIOSYSTEMATIC CODES:
86215 Hominidae

3/9/5 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

13932317 BIOSIS NO.: 199799566377
Immunology of skin aging
AUTHOR: Lotti Torello; Ghersetich Ilaria
AUTHOR ADDRESS: Dep. Dermatology, Univ. Siena, Policlinico le Scotte, Via le Bracci, Siena, Italy**Italy
JOURNAL: Periodicum Biologorum 98 (4): p463-467 1996 1996
ISSN: 0031-5362
DOCUMENT TYPE: Article; Literature Review
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Immune responsiveness has been documented as altered in elderly patients. The major functional change can be explained as a primary defect involving the complex interactions within the T cell system that may permit expression of autoreactive clones of cytotoxic lymphocytes and autoantibody forming B cell in the ability of Langerhans' cells, playing an important role in antigen presentation and processing, to present and process antigens, may account in part for the age-associated decrease in immune responsiveness observed in the skin. The molecular basis of UV-radiation in inducing human neoplasms in sun-exposed areas have also been studied showing a possible role of the UV-mediated activation of Ha-ras oncogene and mutations in the p53 tumor suppressor gene. A relationship between unrepaired or error-prone repaired DNA, and both aging and carcinogenesis has been suggested as well.

DESCRIPTORS:
MAJOR CONCEPTS: Blood and Lymphatics--Transport and Circulation; Immune System--Chemical Coordination and Homeostasis; Integumentary System--Chemical Coordination and Homeostasis; Radiology--Medical Sciences; Tumor Biology
MISCELLANEOUS TERMS: AGING; B CELLS; BLOOD AND LYMPHATICS; DAMAGE; DNA; IMMUNE CONTROL; IMMUNE SYSTEM; INTEGUMENTARY SYSTEM; PHOTOCARCINOGENESIS; REPAIR; SKIN; T CELLS; TUMOR BIOLOGY; Literature Review
CONCEPT CODES:
06504 Radiation biology - Radiation and isotope techniques
15008 Blood - Lymphatic tissue and reticuloendothelial system
18506 Integumentary system - Pathology

24007 Neoplasms - Carcinogens and carcinogenesis
34508 Immunology - Immunopathology, tissue immunology

3/9/6 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

14307643 EMBASE No: 2007074243
Calcium-dependent growth regulation of small cell lung cancer cells by neuropeptides
Gudermann T.; Roelle S.
T. Gudermann, Institut fur Pharmakologie und Toxikologie, Philipps-Universitat Marburg, Karl-von-Frisch-Str. 1, 35043 Marburg Germany
AUTHOR EMAIL: guderman@staff.uni-marburg.de
Endocrine-Related Cancer (ENDOCR.-RELAT. CANCER) (United Kingdom)
2006, 13/4 (1069-1084)
CODEN: ERCAE ISSN: 1351-0088
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 134

Approximately 15-25% of all primary cancers of the lung are classified histologically as small cell lung carcinoma (SCLC), a subtype characterized by rapid growth and a poor prognosis. Neuropeptide hormones like bombesin/gastrin-releasing peptide, bradykinin or galanin are the principal mitogenic stimuli of this tumour entity. The mitogenic signal is transmitted into the cell via heptahelical neuropeptide hormone receptors, which couple to the heterotrimeric G proteins of the GSUBq/11 familiy. Subsequent activation of phospholipase Cbeta (PLCbeta) entails the activation of protein kinase C and the elevation of the intracellular calcium concentration. There is mounting evidence to support the notion that calcium mobilization is the key event that initiates different mitogen-activated protein kinase cascades. Neuropeptide-dependent proliferation of SCLC cells relies on parallel activation of the GSUBq/11/PLCbeta/Ras/extracellular signal-regulated kinase and the c-jun N-terminal kinase pathways, while selective engagement of either signalling cascade alone results in growth arrest and differentiation or apoptotic cell death. Basic experimental research has the potential to identify and validate novel therapeutic targets located at critical points of convergence of different mitogenic signal transduction pathways. In the case of SCLC, targeting the distinct components of the CaSUP2+ influx pathway as well as critical CaSUP2+-dependent cellular effectors may be rewarding in this regard. (c) 2006 Society for Endocrinology.

DRUG DESCRIPTORS:
5 amino 1 [3,5 dichloro 4 (4 chlorobenzoyl)benzyl] 1h 1,2,3 triazole 4 carboxamide--pharmacology--pd; autoantibody--pharmacology--pd; bombesin; cisplatin--pharmacology--pd; etoposide--pharmacology--pd; gastrin releasing peptide; guanine nucleotide binding protein; imatinib--pharmacology--pd; mitogen activated protein kinase; neuropeptide; phospholipase C beta1; protein kinase C; stress activated protein kinase; substance P derivative --clinical trial--ct; substance P derivative--drug therapy--dt
MEDICAL DESCRIPTORS:
*lung small cell cancer--drug therapy--dt
apoptosis; calcium cell level; calcium mobilization; calcium transport; cancer cell; cell death; cell differentiation; cell growth; cell proliferation; clinical trial; enzyme activation; growth regulation; human; nonhuman; protein phosphorylation; review; signal transduction

CAS REGISTRY NO.: 99519-84-3 (5 amino 1 [3,5 dichloro 4 (4 chlorobenzoyl)benzyl] 1h 1,2,3 triazole 4 carboxamide); 31362-50-2 (bombesin); 15663-27-1, 26035-31-4, 96081-74-2 (cisplatin); 33419-42-0 (etoposide); 74815-57-9, 80043-53-4 (gastrin releasing peptide); 152459-95-5, 220127-57-1 (imatinib); 142243-02-5 (mitogen activated protein kinase); 141436-78-4 (protein kinase C); 155215-87-5 (stress activated protein kinase)
SECTION HEADINGS:
015 Chest Diseases, Thoracic Surgery and Tuberculosis
016 Cancer
029 Clinical and Experimental Biochemistry
030 Clinical and Experimental Pharmacology
037 Drug Literature Index

3/9/7 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE

12925604 EMBASE No: 2004527073
Emerging molecular biomarkers for early detection of lung cancer in patients at high risk
Price N.; Jain V.K.; Belani C.P.
Clinical Lung Cancer (CLIN. LUNG CANCER) (United States) 2004, 6/3 (145-148)
CODEN: CLCLC ISSN: 1525-7304
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 19
DRUG DESCRIPTORS:
*biological marker--endogenous compound--ec
Ki 67 antigen--endogenous compound--ec; protein p53--endogenous compound --ec; epidermal growth factor receptor--endogenous compound--ec; K ras protein--endogenous compound--ec; telomerase--endogenous compound--ec; DNA --endogenous compound--ec; autoantibody--endogenous compound--ec; heparin binding epidermal growth factor--endogenous compound--ec; glutathione --endogenous compound--ec; glutathione transferase--endogenous compound--ec ; protein p21--endogenous compound--ec; APC protein--endogenous compound --ec; cadherin--endogenous compound--ec; protein p16--endogenous compound --ec; cyclin dependent kinase inhibitor--endogenous compound--ec; fragile histidine triad protein--endogenous compound--ec; methylated DNA protein cysteine methyltransferase--endogenous compound--ec; retinoic acid receptor beta--endogenous compound--ec; Ras protein--endogenous compound--ec; unclassified drug
MEDICAL DESCRIPTORS:
*lung cancer--diagnosis--di; *lung cancer--etiology--et
early diagnosis; high risk patient; cancer screening; histopathology; genetic screening; proteomics; lung lavage; bronchus biopsy; sputum analysis; aspiration biopsy; molecular dynamics; diagnostic accuracy; malignant transformation; lung non small cell cancer--diagnosis--di; lung non small cell cancer--etiology--et; gene expression; mutational analysis; chromosome aberration; DNA methylation; lung small cell cancer--diagnosis --di; lung small cell cancer--etiology--et; gene silencing; CpG island; human; article
DRUG TERMS (UNCONTROLLED): pleiotropin--endogenous compound--ec
CAS REGISTRY NO.: 9007-49-2 (DNA); 154531-34-7 (heparin binding epidermal growth factor); 70-18-8 (glutathione); 50812-37-8 (glutathione transferase); 85306-28-1 (protein p21); 174068-12-3 (fragile histidine triad protein)
SECTION HEADINGS:

005 General Pathology and Pathological Anatomy
015 Chest Diseases, Thoracic Surgery and Tuberculosis
016 Cancer
022 Human Genetics
029 Clinical and Experimental Biochemistry

3/9/8 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE

11995435 EMBASE No: 2003105798
Peptide and protein drug delivery to and into tumors: Challenges and solutions
Torchilin V.P.; Lukyanov A.N.
V.P. Torchilin, Dept. of Pharmaceutical Sciences, Bouve College of Health Sciences, Northeastern University, 360 Huntington Ave, Boston, MA 02115 United States
AUTHOR EMAIL: v.torchilin@neu.edu
Drug Discovery Today (DRUG DISCOV. TODAY) (United Kingdom) 15 MAR 2003, 8/6 (259-266)
CODEN: DDTOF ISSN: 1359-6446
PUBLISHER ITEM IDENTIFIER: S1359644603026230
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 80

The potential of peptide and protein anticancer agents has yet to be realized owing to the many unresolved problems concerning their delivery to the site of a tumor and into tumor cells. However, our understanding of the mechanisms underlying the biological fate and biodistribution of protein and peptide drugs has advanced to the stage where methods that use or influence these mechanisms are now available. There are different approaches that can improve the stability, longevity and targeting of peptides and proteins in the body, such as their modification with various soluble polymers, incorporation into microparticular drug carriers, enhanced permeability and retention effect-based tumor targeting and the use of targeting moieties. Furthermore, new approaches to intracellular drug delivery, including the use of transduction proteins and peptides, are being developed. These advances promise the delivery of a new generation of anticancer drugs.

BRAND NAME/MANUFACTURER NAME: oncospar/Enzon; doxil/Alza; rituxan
MANUFACTURER NAMES: Enzon; Alza
DRUG DESCRIPTORS:
*antineoplastic agent--drug combination--cb; *antineoplastic agent --pharmacoeconomics--pe; *antineoplastic agent--pharmaceutics--pr; * antineoplastic agent--pharmacokinetics--pk; *antineoplastic agent --pharmacology--pd
drug carrier; somatostatin derivative; octreotide; angiopeptin; vapreotide; endostatin; asparaginase--pharmacoeconomics--pe; asparaginase --pharmaceutics--pr; asparaginase--pharmacokinetics--pk; trastuzumab--drug combination--cb; trastuzumab--pharmacology--pd; rituximab--pharmacology--pd ; paclitaxel--drug combination--cb; paclitaxel--pharmacology--pd; macrogol --pharmaceutics--pr; alpha2b interferon--pharmacoeconomics--pe; alpha2b interferon--pharmacology--pd; styrene maleic anhydride copolymer --pharmaceutics--pr; immunoliposome--pharmaceutics--pr; immunoliposome --pharmacology--pd; daunorubicin--pharmaceutics--pr; doxorubicin --pharmaceutics--pr; doxorubicin--pharmacology--pd; antinuclear antibody --pharmaceutics--pr; antinuclear antibody--pharmacology--pd; immunotoxin

--pharmaceutics--pr; Ras protein; Raf protein; transactivator protein --pharmacology--pd; unclassified drug
MEDICAL DESCRIPTORS:
*drug delivery system; *tumor
drug distribution; drug activity; drug tolerability; peptide synthesis; reticuloendothelial system; drug mechanism; drug elimination; conjugation; drug approval; drug penetration; drug retention; macromolecule; micelle; drug formulation; cancer therapy; endocytosis; signal transduction; human; review
DRUG TERMS (UNCONTROLLED): antinuclear autoantibody 2c5--pharmaceutics--pr; antinuclear autoantibody 2c5--pharmacology--pd; antinuclear autoantibody 1G3--pharmaceutics--pr; antinuclear autoantibody 1G3--pharmacology--pd; oncospar
CAS REGISTRY NO.: 83150-76-9 (octreotide); 113294-82-9 (angiopeptin); 103222-11-3 (vapreotide); 187888-07-9 (endostatin); 9015-68-3 (asparaginase); 180288-69-1 (trastuzumab); 174722-31-7 (rituximab); 33069-62-4 (paclitaxel); 25322-68-3 (macrogol); 99210-65-8 (alpha2b interferon); 9011-13-6 (styrene maleic anhydride copolymer); 12707-28-7 , 20830-81-3, 23541-50-6 (daunorubicin); 23214-92-8, 25316-40-9 (doxorubicin)
SECTION HEADINGS:
016 Cancer
036 Health Policy, Economics and Management
037 Drug Literature Index
039 Pharmacy

3/9/9 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE

06549331 EMBASE No: 1996211332
Skin aging, immunosurveillance and cancer
Ghersetich I.; Teofoli P.; Lotti T.
Viale Dante Alighieri 23,Montecatini Terme (PT) Italy
Skin Cancer (SKIN CANCER) (Portugal) 1996, 11/1 (103-110)
CODEN: SKCAE ISSN: 0871-2549
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Cutaneous aging includes two distinct phenomena: true aging that describes an intrinsic physiologic process and photo-aging, due to chronic sun exposure. Major age-related changes in appearance are associated with microscopic modification and declining of numerous functions. Immune responsiveness has been documented altered in elderly patients and major functional change can be explained as a primary defect involving the complex interactions within the T-cell system that may permit expression of autoreactive clones of cytotoxic lymphocytes and autoantibody forming B-cell in the elderly. In photo-aged skin, the documented progressive decrease in the ability of Langerhans cells, playing an important role in antigen presentation and processing, to present and process antigens, may account in part for the age-associated decrease in immune responsiveness observed in the skin. The molecular basis of UV-radiation in inducing human neoplasms in sun- exposed areas have also been studied, showing a possible role of the UV- mediated activation of Ha-ras oncogene and mutations in the p53 tumour suppressor gene. A relationship between unrepaired or error-prone repaired DNA and both aging and carcinogenesis has also been suggested.

MEDICAL DESCRIPTORS:

*aging; *skin; *skin cancer
antibody production; article; cytotoxic t lymphocyte; dna damage; dna repair; gene expression; human; human tissue; immune system; skin carcinogenesis; sun exposure; ultraviolet radiation
SECTION HEADINGS:
013 Dermatology and Venereology

3/9/10 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE

06282348 EMBASE No: 1995308411
Antibody to ras proteins in patients with colon cancer
Takahashi M.; Chen W.; Byrd D.R.; Disis M.L.; Huseby E.S.; Qin H.; McCahill L.; Nelson H.; Shimada H.; Okuno K.; Yasutomi M.; Peace D.J.; Cheever M.A.
Division of Oncology, University of Washington,Seattle, WA 98195-6527 United States
Clinical Cancer Research (CLIN. CANC. RES.) (United States) 1995, 1/10 (1071-1077)
CODEN: CCREF ISSN: 1078-0432
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

The current study examined sera from 160 colon cancer patients and 60 normal individuals to determine whether antibody to mutated p21 ras protein was present. Studies focused on the aspartic acid substitution at amino acid position 12 (denoted D12), one of the most common mutations in colon adenocarcinoma. IgA antibodies directed against mutated p21 ras-D12 protein were detected in 51 (32%) of 160 colon cancer patients, but only in 1 (2.5%) of 40 normal individuals. The greater incidence of antibody in cancer patients provides presumptive evidence that immunization to the ras proteins occurred as a result of the malignancy. Examination of sera for antibody reactivity to wild-type p21 ras protein (denoted p21 ras-G12) as well as p21 ras proteins bearing the D12, V12, S12, or L61 mutations showed that antibody detected was largely to normal segments of the p21 ras protein. Epitope mapping, using peptide neutralization assays with mutated or normal ras peptides as competitors, demonstrated that in 10 (67%) of 15 sera examined the antibody reactivity to p21 ras-G12 protein was neutralized by peptides near the carboxyl terminus of p21 ras protein, but not by peptides spanning the specific point mutation region. Antibody reactivities correlated with peripheral blood lymphocyte count, but did not correlate with patient age, sex, histology, stage, tumor locus, lymph node metastasis, or scrum carcinoembryonic antigen.

DRUG DESCRIPTORS:
*autoantibody--endogenous compound--ec; *oncoprotein--endogenous compound --ec; *protein p21--endogenous compound--ec
MEDICAL DESCRIPTORS:
*colon cancer; *oncogene ras
adult; aged; amino acid substitution; article; blood level; controlled study; female; gene mutation; human; lymphocyte count; major clinical study ; male; priority journal
CAS REGISTRY NO.: 85306-28-1 (protein p21)
SECTION HEADINGS:
016 Cancer
022 Human Genetics
026 Immunology, Serology and Transplantation
029 Clinical and Experimental Biochemistry

048 Gastroenterology

3/9/11 (Item 6 from file: 73)
DIALOG(R)File 73:EMBASE

04344317 EMBASE No: 1990232380
Association of EGF receptor expression with proliferating cells and of ras p21 expression with differentiating cells in various skin tumours
Kikuchi A.; Amagai M.; Hayakawa K.; Ueda M.; Hirohashi S.; Shimizu N.; Nishikawa T.
Department of Dermatology, Keio University School of Med., 35 Shinanomachi,Shinjuku-ku, Tokyo 160 Japan
British Journal of Dermatology (BR. J. DERMATOL.) (United Kingdom) 1990, 123/1 (49-58)
CODEN: BJDEA ISSN: 0007-0963
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

The localization of DNA replicating cells, epidermal growth factor (EGF) receptor-expressing cells and ras oncogene product p21 (p-21(ras)) positive cells were examined in various skin tumours to elucidate the role of EGF receptor and p21(ras) in the epidermis. Normal skin, keratoacanthoma (KA), solar keratosis (SK), Bowen's disease (BD), squamous cell carcinoma (SCC), basal cell carcinoma (BCC) and extramammary Paget's disease (PD) were studied. EGF receptors were seen in proliferating layers, where DNA replicating cells localize, but p21(ras) was found in the more differentiated layers. We conclude that EGF receptor expression is closely associated with cellular proliferation, but p21(ras) may play a role in the differentiation of cells in various skin tumours.

DRUG DESCRIPTORS:
*epidermal growth factor receptor
autoantibody
MEDICAL DESCRIPTORS:
*keratoacanthoma; *keratosis; *oncogene ras; *paget skin disease; *skin tumor--etiology--et; *squamous cell carcinoma--etiology--et
histology; human cell; human; article; priority journal
SECTION HEADINGS:
005 General Pathology and Pathological Anatomy
013 Dermatology and Venereology
016 Cancer
026 Immunology, Serology and Transplantation

3/9/12 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

11181776 Genuine Article#: 618PJ Number of References: 38
Title: Characterisation of tumour-associated antigens in colon cancer
Author(s): Line A (REPRINT) ; Slucka Z; Stengrevics A; Silina K; Li G; Rees RC
Corporate Source: Univ Latvia,Biomed Res & Study Ctr,1 Ratsupites St/LV-1067 Riga//Latvia/ (REPRINT); Univ Latvia,Biomed Res & Study Ctr,LV-1067 Riga//Latvia/; Latvian Oncol Ctr,Riga//Latvia/; Nottingham Trent Univ,Dept Life Sci,Nottingham//England/
Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY, 2002, V51, N10 (NOV), P574-582
ISSN: 0340-7004 Publication date: 20021100

Publisher: SPRINGER-VERLAG, 175 FIFTH AVE, NEW YORK, NY 10010 USA
Language: English Document Type: ARTICLE
Geographic Location: Latvia; England
Journal Subject Category: ONCOLOGY; IMMUNOLOGY
Abstract: In order to search for clinically relevant cancer-associated genes and to define further the spectrum of immunogenic proteins, we applied SEREX (serological identification of antigens by recombinant expression cloning) to analyse genes expressed in colon adenocarcinoma. Eight different serum-reactive cDNA clones were isolated by immunoscreening from a colon cancer-derived cDNA expression library. mRNA expression studies showed that 2 of them, RHAMM and AD034, have a differential tissue distribution, and that 3 genes, NAP1L1, RHAMM and AD034, are overexpressed in tumours in comparison with the adjacent non-cancerous tissues. 5' RLM-RACE analysis of AD034, a sequence with a tyrosine kinase motif, revealed a frameshifting insertion of 32 bp, most likely generated by use of cryptic splice site in tumour-derived cDNA. Analysis of full-length RHAMM cDNA sequence revealed the presence of two splice variants, which are known to have a different sub-cellular localisation; expression of these splice variants is altered in colon cancer tissues. Serological responses to three antigens (C21ORF2, EPRS and NAP1L1) were found mainly in cancer patients' sera.
Descriptors--Author Keywords: AD034 ; autoantibody ; NAP1L1 ; RHAMM ; SEREX
Identifiers--KeyWord Plus(R): RAS-TRANSFORMED CELLS; HYALURONAN RECEPTOR; BINDING-PROTEIN; IMMUNE-RESPONSES; HUMAN-DISEASE; GENE-PRODUCT; RHAMM; IDENTIFICATION; EXPRESSION; LOCOMOTION
Cited References:
ABETAMANN V, 1996, V2, P1607, CLIN CANCER RES
ALI SA, 2002, V168, P3512, J IMMUNOL
ASSMANN V, 1998, V111, P1685, J CELL SCI 12
ASSMANN V, 1999, V112, P3943, J CELL SCI
ASSMANN V, 2001, V195, P191, J PATHOL
CHEN YT, 1997, V94, P1914, P NATL ACAD SCI USA
COOPER TA, 1997, V61, P259, AM J HUM GENET
DUVAL A, 2001, V10, P513, HUM MOL GENET
HALL CL, 1995, V26, P221, J NEURO-ONCOL
HARDWICK C, 1992, V117, P1343, J CELL BIOL
HOFMANN M, 1998, V111, P1673, J CELL SCI 12
JAGER E, 2000, V97, P4760, P NATL ACAD SCI USA
JAGER E, 2000, V97, P12198, P NATL ACAD SCI USA
JAGER D, 1999, V59, P6197, CANCER RES
KNIGHTS AJ, 2002, V51, P271, CANCER IMMUNOL IMMUN
LANZAVECCHIA A, 1999, V96, P1, CELL
LI H, 2000, V17, P927, INT J ONCOL
LINE A, 2002, V86, P1824, BRIT J CANCER
MAIN S, 2001, P1, CANC IMMUNOLOGY
MASHINO K, 2001, V85, P713, BRIT J CANCER
PFREUNDSCHUH M, 2000, V46, PS3, CANCER CHEMOTH PHA S
PHILIPS AV, 2000, V57, P235, CELL MOL LIFE SCI
REES RC, 2002, V51, P58, CANCER IMMUNOL IMMUN
SAHIN U, 1995, V92, P11810, P NATL ACAD SCI USA
SAHIN U, 2001, P45, CANC IMMUNOLOGY
SCANLAN MJ, 1998, V76, P652, INT J CANCER
SHERMAN L, 1994, V6, P726, CURR OPIN CELL BIOL
SIMON HU, 1994, V297, P389, BIOCHEM J
STOCKERT E, 1998, V187, P1349, J EXP MED
TOH Y, 1997, V74, P459, INT J CANCER
TOH Y, 1999, V79, P1723, BRIT J CANCER
TURECI O, 1997, V272, P6416, J BIOL CHEM
TURECI O, 1999, V18, P23, HYBRIDOMA

TURLEY EA, 1993, V207, P277, EXP CELL RES
TURLEY EA, 1991, V112, P1041, J CELL BIOL
VIOLA A, 1996, V273, P104, SCIENCE
WANG YM, 2000, V4, P7, MED IMAGE ANAL
YAMADA Y, 1999, V90, P987, JPN J CANCER RES

3/9/13 (Item 2 from file: 34)

DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

05345913 Genuine Article#: VT338 Number of References: 49

Title: OVEREXPRESSION OF CYSTEINE SULFINIC ACID DECARBOXYLASE STIMULATED BY HEPATOCARCINOGENESIS RESULTS IN AUTOANTIBODY PRODUCTION IN RATS

Author(s): KISHIMOTO T; KOKURA K; NAKADAI T; MIYAZAWA Y; WAKAMATSU T; MAKINO Y; NAKAMURA T; HARA E; ODA K; MURAMATSU M; TAMURA T
Corporate Source: CHIBA UNIV,FAC SCI,DEPT BIOL,INAGE KU,1-33 YAYOI/CHIBA 263//JAPAN/; CHIBA UNIV,FAC SCI,DEPT BIOL,INAGE KU/CHIBA 263//JAPAN/; SUMITOMO ELECT IND LTD,BIOMED RES & DEV DEPT,SAKAE KU,TAYA CHO/YOKOHAMA/KANAGAWA 254/JAPAN/; SCI UNIV TOKYO,DEPT BIOL SCI & TECHNOL/NODA/CHIBA 278/JAPAN/; SAITAMA MED SCH,FAC MED,DEPT BIOCHEM/MOROYAMA/SAITAMA 35004/JAPAN/
Journal: CANCER RESEARCH, 1996, V56, N22 (NOV 15), P5230-5237
ISSN: 0008-5472
Language: ENGLISH Document Type: ARTICLE
Geographic Location: JAPAN
Subfile: SciSearch; CC LIFE--Current Contents, Life Sciences; CC CLIN--Current Contents, Clinical Medicine
Journal Subject Category: ONCOLOGY
Abstract: We developed a novel and efficient cDNA subtraction method to isolate rat hepatocellular carcinoma (HCC)-related genes. cDNAs from Solt-Farber procedure-driven HCCs were synthesized on Latex beads. The subtraction was accomplished by a simple centrifugation, PCR amplification, and dot blot screening. Among 2000 clones from the subtracted cDNA library, one clone with a full-length HCC-related cDNA was eventually obtained. Sequence analysis of this clone showed it to exhibit 90 and 60% similarity with the rat cysteine sulfinic: acid decarboxylase (CSAD) and mammalian glutamic acid decarboxylases (GAD), respectively. Differences between our sequence data on CSAD and those reported previously were observed at two positions, which arose from a single amino acid substitution and frame shift mutation. The CSAD expression was restricted to the liver and kidney of rats. During hepatocarcinogenesis, expression of the CSAD mRNA and its protein was stimulated in the precancerous liver and maintained its high expression afterward. Interestingly, a high level of anti-CSAD autoantibody was detected in the HCC-bearing rats. The titer of anti-CSAD autoantibodies in these rats was 30-200 times higher than that in normal rats. The anti-CSAD autoantibody appeared in the precancerous state and was maintained afterward, and its pattern of appearance was similar to that of CSAD mRNAs and proteins. Thus, we propose that the high-titer CSAD autoantibody resulted from increased CSAD gene expression in the liver due to stimulation by the HCC. These results remind us of human autoimmune diseases including insulin-dependent diabetes mellitus and stiff-man syndrome, which are caused by autoantibodies against GAD.
Identifiers--KeyWords Plus: HEPATITIS-B VIRUS; TUMOR-NECROSIS-FACTOR; STIFF-MAN SYNDROME; HEPATOCELLULAR-CARCINOMA; MOLECULAR-CLONING; CDNA CLONING; LEC RATS; GLUTAMATE-DECARBOXYLASE; GENE-EXPRESSION; FUSION PROTEIN
Research Fronts: 94-2087 002 (HEPATITIS-B VIRUS; Z-NUMBER-2 ALPHA(1)-ANTITRYPSIN TRANSGENIC MICE; RAF-DEPENDENT ACTIVATION OF C-JUN

TRANSCRIPTIONAL ACTIVITY)
94-3169 002 (P53 GENE; KI-RAS EXON-1 MUTATIONS; RETINOBLASTOMA PROTEIN STATE IN HUMAN HEPATOCELLULAR-CARCINOMA)
94-1384 001 (GLUTAMIC-ACID DECARBOXYLASE ANTIBODIES; INSULIN-DEPENDENT DIABETES-MELLITUS; RISK FOR IDDM)
94-3070 001 (RAT SKELETAL-MUSCLE; DEVELOPMENTAL REGULATION; YEAST SACCHAROMYCES-CEREVISIAE)
94-5343 001 (RAT HEPATOCARCINOGENESIS; GAMMA-GLUTAMYL-TRANSPEPTIDASE POSITIVE FOCI; HEPATOCYTES IN CHEMICAL CARCINOGENESIS; CHRONIC LIVER-DISEASE)
94-8153 001 (RECOMBINANT GENES IN ESCHERICHIA-COLI; PROTEIN-PROTEIN INTERACTIONS; DNA-BINDING DOMAINS; PACA SUBUNIT; TYROSINE PHOSPHORYLATION)

Cited References:

ANDERSON KP, 1990, V4, P543, MOL ENDOCRINOL
BAEKKESKOV S, 1990, V347, P151, NATURE
BEASLEY RP, 1981, V2, P1129, LANCET
BHANDARI BN, 1995, V46, P309, ANNU REV MED
BISHOP JM, 1983, V52, P301, ANNU REV BIOCHEM
BJORK E, 1994, V43, P161, DIABETES
BRESSAC B, 1991, V350, P429, NATURE
BU DF, 1992, V89, P2115, P NATL ACAD SCI USA
BUKH J, 1993, V90, P1848, P NATL ACAD SCI USA
BUTLER MH, 1993, V178, P2097, J EXP MED
CALKINS CC, 1995, V376, P71, BIOL CHEM H-S
CASELMANN WH, 1995, V22, P34, J HEPATOL
GUBLER U, 1983, V25, P263, GENE
HARA E, 1993, V214, P58, ANAL BIOCHEM
HARA E, 1991, V19, P7097, NUCLEIC ACIDS RES
HESSE H, 1995, V23, P3355, NUCLEIC ACIDS RES
HSU IC, 1991, V350, P427, NATURE
HUANG WM, 1990, V87, P8491, P NATL ACAD SCI USA
JULIEN JF, 1990, V54, P703, J NEUROCHEM
JULIEN JF, 1987, V73, P173, NEUROSCI LETT
KAISAKIA PJ, 1995, V1262, P79, BBA-GENE STRUCT EXPR
KARLSEN AE, 1991, V88, P8337, P NATL ACAD SCI USA
KAUFMAN DL, 1986, V232, P1138, SCIENCE
KIM CM, 1991, V351, P317, NATURE
KITAHARA A, 1983, V112, P20, BIOCHEM BIOPH RES CO
KOBAYASHI Y, 1987, V7, P2768, J NEUROSCI
KONDO S, 1992, V12, P4496, MOL CELL BIOL
LEGAY F, 1987, V48, P345, J NEUROCHEM
LOYER P, 1993, V336, P215, FEBS LETT
LUQMANI YA, 1994, V222, P102, ANAL BIOCHEM
MICHELSEN BK, 1991, V88, P8754, P NATL ACAD SCI USA
MIYOSHI E, 1993, V53, P3899, CANCER RES
MIYOSHI E, 1993, V14, P603, CARCINOGENESIS
OKAYAMA H, 1987, V154, P3, METHOD ENZYMOL
PIRISI M, 1995, V55, P111, CANCER RES
ROSENBERG AH, 1987, V56, P125, GENE
SAKAMOTO H, 1993, V84, P966, JPN J CANCER RES
SOLT D, 1976, V263, P701, NATURE
STRAUSBAUCH PH, 1970, V9, P233, BIOCHEMISTRY-US
SUGIOKA Y, 1985, V45, P365, CANCER RES
TAKANO M, 1995, V1265, P189, BBA-MOL CELL RES
TOWBIN H, 1979, V76, P4350, P NATL ACAD SCI USA
TWU JS, 1993, V192, P346, VIROLOGY
USUI H, 1994, V14, P4915, J NEUROSCI
WEINSTEIN CL, 1987, V262, P7254, J BIOL CHEM
YEWDELL JW, 1992, V52, P1, ADV IMMUNOL

ZENG J, 1994, V22, P4381, NUCLEIC ACIDS RES
ZIMMERMANN CR, 1980, V21, P709, CELL
ZINKERNAGEL RM, 1979, V27, P51, ADV IMMUNOL

3/9/14 (Item 3 from file: 34)

DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

01994616 Genuine Article#: JT248 Number of References: 102

Title: AUTOANTIBODIES AGAINST SMALL CYTOPLASMIC RIBONUCLEOPROTEINS - THE ANTI-RO SS-A AND ANTI-LA SS-B AUTOIMMUNE-RESPONSE - A REVIEW OF AUTOANTIBODY DETECTION, AUTOANTIGEN COMPOSITION, AUTOANTIBODY-DISEASE ASSOCIATIONS AND POSSIBLE ETIOLOGIC MECHANISMS

Author(s): MEILOF JF
Corporate Source: NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,DEPT AUTOIMMUNE DIS,PLESMANLAAN 125/1066 CX AMSTERDAM//NETHERLANDS/
Journal: RHEUMATOLOGY INTERNATIONAL, 1992, V12, N4 (SEP), P129-140
ISSN: 0172-8172
Language: ENGLISH Document Type: REVIEW
Geographic Location: NETHERLANDS
Subfile: SciSearch; CC LIFE--Current Contents, Life Sciences; CC CLIN--Current Contents, Clinical Medicine
Journal Subject Category: RHEUMATOLOGY
Descriptors--Author Keywords: ANTI-RO/SS-A ANTIBODIES ; ANTI-LA/SS-B ANTIBODIES ; RIBONUCLEOPROTEINS ; CALRETICULIN ; CONGENITAL HEART BLOCK
Identifiers--KeyWords Plus: SYSTEMIC LUPUS-ERYTHEMATOSUS; EPSTEIN-BARR VIRUS; PRIMARY SJOGRENS-SYNDROME; CONGENITAL HEART-BLOCK; CONNECTIVE-TISSUE DISEASE; CALCIUM-BINDING PROTEIN; RO/SS-A; ANTINUCLEAR ANTIBODIES; RHEUMATOID-ARTHRITIS; NEONATAL LUPUS
Research Fronts: 90-0211 002 (PRE-MESSENGER-RNA SPLICING; YEAST U6 SNRNP; MAMMALIAN PROTEIN; CONSERVED DOMAINS)
90-0607 002 (FETAL ECHOCARDIOGRAPHY; CONGENITAL HEART-DISEASE; CHARGE ASSOCIATION; SIMULTANEOUS PULSED DOPPLER VELOCIMETRY)
90-0093 001 (RECOMBINANT INTERLEUKIN-2; LYMPHOKINE-ACTIVATED KILLER-CELLS; TUMOR-INFILTRATING LYMPHOCYTES; CANCER-PATIENTS RECEIVING ADOPTIVE IMMUNOTHERAPY)
90-0547 001 (SYSTEMIC LUPUS-ERYTHEMATOSUS; SJOGRENS-SYNDROME MIMICKING MULTIPLE-SCLEROSIS; ANTI-LA ANTIBODIES; RO RIBONUCLEOPROTEIN-PARTICLES; HUMAN RO/SS-A AUTOANTIGEN)
90-0712 001 (T-CELL RECEPTOR; CLONAL DELETION; TRANSGENIC MICE; PERIPHERAL MECHANISMS INDUCING TISSUE TOLERANCE; MHC CLASS-II MOLECULES)
90-3110 001 (IDENTIFICATION OF FRAGMENTS; CORTICOSTEROIDS INCREASE LIPOCORTIN-I; RAS ADENYLATE-CYCLASE PATHWAY; HEAT-SHOCK PROTEIN HSP70 FAMILY)
Cited References:
ALSPAUGH M, 1979, V22, P796, ARTHRITIS RHEUM
ALSPAUGH MA, 1975, V55, P1067, J CLIN INVEST
BACHMANN M, 1990, V60, P85, CELL
BACHMANN M, 1986, V83, P7770, P NATL ACAD SCI USA
BENCHETRIT E, 1989, V83, P1284, J CLIN INVEST
BENCHETRIT E, 1988, V167, P1560, J EXP MED
BINI P, 1990, V85, P325, J CLIN INVEST
BOIRE G, 1991, V34, P722, ARTHRITIS RHEUM
BOOTH C, 1989, V59, P729, CELL
BUYON JP, 1989, V84, P627, J CLIN INVEST
CHAMBERS JC, 1988, V263, P8043, J BIOL CHEM
CHAMBERS JC, 1985, V82, P2115, P NATL ACAD SCI USA
CHAN EKL, 1990, V33, S73, ARTHRITIS RHEUM

CHAN EKL, 1991, V87, P68, J CLIN INVEST
CHAN EKL, 1986, V136, P3744, J IMMUNOL
CLARK G, 1969, V102, P117, J IMMUNOL
COLLINS JH, 1989, V164, P575, BIOCHEM BIOPH RES CO
DERKSEN RHW, 1992, IN PRESS ARTHRITIS R
DEUTSCHER SL, 1988, V85, P9479, P NATL ACAD SCI USA
ELKON KB, 1984, V132, P2350, J IMMUNOL
EZPARZA RH, 1986, V13, P327, J RHEUMATOL
FLESCHER E, 1991, V90, P283, AM J MED
FLIEGEL L, 1989, V264, P1522, J BIOL CHEM
FOX RI, 1986, V137, P3162, J IMMUNOL
FRIEDMAN SM, 1991, V34, P468, ARTHRITIS RHEUM
GAITHER KK, 1987, V79, P841, J CLIN INVEST
GHARAVI AE, 1986, V6, P61, RHEUMATOL INT
GORDON TP, 1991, V85, P402, CLIN EXP IMMUNOL
GOTTLIEB E, 1989, V8, P851, EMBO J
HABETS WJ, 1983, V2, P1625, EMBO J
HABETS WJA, 1989, V76, P172, CLIN EXP IMMUNOL
HADLACZKY G, 1989, V97, P282, CHROMOSOMA
HANSEN B, 1988, V43, P577, ALLERGY
HARLEY JB, 1985, V76, P801, J CLIN INVEST
HARLEY JB, 1984, V11, P309, J RHEUMATOL
HOLMAN HR, 1957, V126, P162, SCIENCE
HORSFALL AC, 1990, V33, S50, ARTHRITIS RHEUM
HORSFALL AC, 1991, V12, P211, IMMUNOL TODAY
ITOH K, 1991, V87, P177, J CLIN INVEST
ITOH Y, 1991, V15, P197, MOL BIOL REP
JAMES JA, 1990, V33, P102, ARTHRITIS RHEUM
KAPPLER J, 1989, V244, P811, SCIENCE
KOHSAKA H, 1990, V85, P1566, J CLIN INVEST
KRIEG AM, 1989, V32, P322, ARTHRITIS RHEUM
LAVER WG, 1990, V61, P553, CELL
LERNER MR, 1980, V283, P220, NATURE
LERNER MR, 1979, V76, P5495, P NATL ACAD SCI USA
LERNER MR, 1981, V78, P805, P NATL ACAD SCI USA
LIEU TS, 1988, V82, P96, J CLIN INVEST
LIEU TS, 1984, V71, P217, J IMMUNOL METHODS
LIN RH, 1991, V173, P1433, J EXP MED
LITSEY SE, 1985, V312, P98, NEW ENGL J MED
LORD PCW, 1989, V70, P2383, J GEN VIROL
LUX FA, 1990, V33, S125, ARTHRITIS RHEUM
MAMULA MJ, 1986, V86, P1889, J EXP MED
MAMULA MJ, 1989, V143, P2923, J IMMUNOL
MCCAULIFFE DP, 1990, V85, P1379, J CLIN INVEST
MCNEILAGE LJ, 1990, V145, P3829, J IMMUNOL
MEILOF JF, IN PRESS ARTHRITIS R
MEILOF JF, 1990, V133, P215, J IMMUNOL METHODS
MEILOF JF, 1991, V15, P136, MOL BIOL REP
MEILOF JF, 1992, V40, P140, NETH J MED
MILLER FW, 1990, V87, P9933, P NATL ACAD SCI USA
MOURAD W, 1989, V170, P2011, J EXP MED
NYMAN U, 1989, V22, P65, IMMUNOL LETT
OBRIEN CA, 1990, V9, P3683, EMBO J
PALIARD X, 1991, V253, P325, SCIENCE
RADER MD, 1989, V32, P1563, ARTHRITIS RHEUM
RADER MD, 1989, V83, P1293, J CLIN INVEST
REICHLIN M, 1989, V76, P373, CLIN EXP IMMUNOL
ROKEACH LA, 1991, V147, P3031, J IMMUNOL
ROSENBERG SA, 1987, V316, P889, NEW ENGL J MED
SAITTA MR, 1991, V15, P176, MOL BIOL REP

SCOFIELD RH, 1991, V88, P3343, P NATL ACAD SCI USA
SCOTT JS, 1983, V309, P209, NEW ENGL J MED
SCULLEY TB, 1986, V29, P964, ARTHRITIS RHEUM
SILVERMAN E, 1991, V18, P120, J RHEUMATOL
SLOBBE RL, 1992, THESIS U NIJMEGEN
SMITH MJ, 1989, V8, P3581, EMBO J
STCLAIR EW, 1990, V85, P515, J CLIN INVEST
STUIVER MH, 1990, V172, P1049, J EXP MED
TALAL N, 1990, V33, P774, ARTHRITIS RHEUM
TAN EM, 1989, V44, P93, ADV IMMUNOL
TAN EM, 1988, V47, P121, CLIN IMMUNOL IMMUNOP
TAN EM, 1989, V84, P1, J CLIN INVEST
TAN EM, 1967, V70, P800, J LAB CLIN MED
TAYLOR PV, 1986, V315, P667, NEW ENGL J MED
TEPPO AM, 1982, V15, P1, SCAND J IMMUNOL
TOWBIN H, 1979, V76, P4350, P NATIONAL ACADEMY S
TUMANG JR, 1990, V171, P2153, J EXP MED
VANDAM A, 1991, V18, P1026, J RHEUMATOL
VANDAM AP, 1990, V81, P31, CLIN EXP IMMUNOL
VANDAM AP, 1990, V129, P63, J IMMUNOL METHODS
VELDHOVEN CHA, 1992, V151, P177, J IMMUNOL METHODS
VENABLES PJW, 1983, V26, P146, ARTHRITIS RHEUM
VENABLES PJW, 1989, V32, P811, ARTHRITIS RHEUM
WATSON RM, 1984, V63, P362, MEDICINE
WHITTINGHAM S, 1987, V2, P1, LANCET
WU DH, 1989, V121, P219, J IMMUNOL METHODS
YAMAGATA H, 1984, V74, P625, J CLIN INVEST
YAMAOKA K, 1988, V31, P1014, ARTHRITIS RHEUM
ZAGOURAS P, 1989, V109, P2633, J CELL BIOL

3/9/15 (Item 4 from file: 34)

01858700 Genuine Article#: JG444 Number of References: 14

Title: CIRCULATING AUTOANTIBODY TO MUSCLE PROTEIN IN A PATIENT WITH PARANEOPLASTIC MYOSITIS AND COLON CANCER

Author(s): UEYAMA H; KUMAMOTO T; ARAKI S
Corporate Source: KUMAMOTO UNIV,SCH MED,DEPT INTERNAL MED 1,HONJO1-1-1/KUMAMOTO 860//JAPAN/

Journal: EUROPEAN NEUROLOGY, 1992, V32, N5 (SEP-OCT), P281-284
Language: ENGLISH Document Type: ARTICLE
Geographic Location: JAPAN
Subfile: SciSearch; CC LIFE--Current Contents, Life Sciences; CC CLIN--Current Contents, Clinical Medicine
Journal Subject Category: CLINICAL NEUROLOGY

Abstract: A muscle-specific autoantibody was found in a patient with paraneoplastic myositis and colon cancer. By immunoblotting, we found high titers of circulating antibody to a 34-kDa neutral protein in the soluble sarcoplasmic fraction of the rat skeletal muscle. The serum did not react at all with other tissue extracts including the central nervous tissue, liver, or kidney. The possible role of this muscle-specific autoantibody in the pathogenesis of paraneoplastic myositis is discussed.

Descriptors--Author Keywords: PARANEOPLASTIC MYOSITIS ; POLYMYOSITIS ; AUTOANTIBODY ; PARANEOPLASTIC SYNDROME ; COLON CANCER
Identifiers--KeyWords Plus: MALIGNANCY
Research Fronts: 90-3110 002 (IDENTIFICATION OF FRAGMENTS; CORTICOSTEROIDS INCREASE LIPOCORTIN-I; RAS ADENYLATE-CYCLASE PATHWAY;

HEAT-SHOCK PROTEIN HSP70 FAMILY)
90-0904 001 (PARANEOPLASTIC CEREBELLAR DEGENERATION; LAMBERT-EATON MYASTHENIC SYNDROME; ANTINEURONAL ANTIBODIES; CALCIUM CHANNELS; SMALL-CELL LUNG-CARCINOMA CELL-LINES)
90-1862 001 (CHILDHOOD DERMATOMYOSITIS; ANTINUCLEAR ANTIBODIES; POLYMYOSITIS SHOW CHANGES IN MUSCLE PROTEIN CHARGES)
Cited References:
ALEXANDER S, 1968, V80, P86, BRIT J DERMATOL
ANDERSON NE, 1988, V24, P559, ANN NEUROL
ARAHATA K, 1988, P313, P NEUROIMMUNOL DIS
BARNES BE, 1976, V84, P68, ANN INTERN MED
CALLEN JP, 1984, V10, P117, CLIN RHEUM DIS
COPEMAN PW, 1967, V60, P183, P ROY SOC MED
GRAUS F, 1986, V80, P45, AM J MED
KIM YI, 1988, V239, P405, SCIENCE
LAEMMLI UK, 1970, V227, P680, NATURE
NIHEI T, 1980, V119, P275, FEBS LETT
OFARRELL PH, 1975, V250, P4007, J BIOL CHEM
POSNER JB, 1989, V9, P245, CURR NEUROL
TOWBIN H, 1979, V76, P4350, P NATIONAL ACADEMY S
VENABLES PJW, 1981, V40, P217, ANN RHEUM DIS

3/9/16 (Item 5 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

01748705 Genuine Article#: HX974 Number of References: 38
Title: HUMAN AUTOANTIBODIES AGAINST DESMOPLAKINS IN PARANEOPLASTIC PEMPHIGUS
Author(s): OURSLER JR; LABIB RS; ARISSABDO L; BURKE T; OKEEFE EJ; ANHALT GJ
Corporate Source: JOHNS HOPKINS UNIV,SCH MED,DEPT DERMATOL,ROOM 771,ROSS RES BLDG,720 RUTLAND AVE/BALTIMORE//MD/21205; JOHNS HOPKINS UNIV,SCH MED,DEPT DERMATOL,ROOM 771,ROSS RES BLDG,720 RUTLAND AVE/BALTIMORE//MD/21205; UNIV N CAROLINA,DEPT DERMATOL/CHAPEL HILL//NC/27514
Journal: JOURNAL OF CLINICAL INVESTIGATION, 1992, V89, N6 (JUN), P1775-1782
Language: ENGLISH Document Type: ARTICLE
Geographic Location: USA
Subfile: SciSearch; CC LIFE--Current Contents, Life Sciences
Journal Subject Category: MEDICINE, RESEARCH & EXPERIMENTAL
Abstract: Recently, a previously unrecognized autoantibody mediated blistering disease, paraneoplastic pemphigus has been described. Paraneoplastic pemphigus is associated with lymphoid malignancies, thymomas, and poorly differentiated sarcomas. Serum of affected patients contain pathogenic autoantibodies that immunoprecipitate from normal keratinocytes a characteristic complex of four polypeptides with M(r) of 250, 230, 210, and 190 kD. As our preliminary studies indicated that the 250-kD and the 210-kD antigens comigrated with desmoplakins I and II, we investigated the possibility that autoantibodies against the desmoplakins were a component of this autoimmune syndrome. 11 sera from affected patients were tested by indirect immunofluorescence against desmosome containing tissues, immunoprecipitation of metabolically labeled keratinocytes, and Western immunoblotting of desmoplakins I and II that had been purified to homogeneity from pig tongue epithelium. By indirect immunofluorescence, 9 of 11 sera showed strong binding to epithelial and nonepithelial desmosomes, and 2 were weakly reactive. All 11 immunoprecipitated 250- and 210-kD bands of variable intensity that comigrated with bands identified by a murine monoclonal antidesmoplakin antibody, and immunoblotting confirmed binding of the

serum autoantibodies to purified desmoplakins. This demonstrates that paraneoplastic pemphigus is the first human autoimmune syndrome in which autoantibodies against the desmoplakins are a prominent component of the humoral autoimmune response.

Descriptors--Author Keywords: PEMPHIGUS ; CELL ADHESION ; DESMOSOMES ; AUTOIMMUNITY ; PARANEOPLASTIC SYNDROMES

Identifiers--KeyWords Plus: NEOPLASTIC CEREBELLAR DEGENERATION; SMALL CELL-CARCINOMA; ANTICEREBELLAR ANTIBODIES; DESMOSOMAL PLAQUE; AUTOIMMUNE BASIS; LUNG-CARCINOMA; PURKINJE-CELLS; GANGLION-CELLS; ANTIGENS; PROTEINS

Research Fronts: 90-0904 001 (PARANEOPLASTIC CEREBELLAR DEGENERATION; LAMBERT-EATON MYASTHENIC SYNDROME; ANTINEURONAL ANTIBODIES; CALCIUM CHANNELS; SMALL-CELL LUNG-CARCINOMA CELL-LINES)

90-1158 001 (BULLOUS PEMPHIGOID; CONGENITAL TOXOPLASMOSIS; INVASIVE FETAL PROCEDURES; IMMUNE THROMBOCYTOPENIC PURPURA; PERCUTANEOUS UMBILICAL BLOOD-SAMPLING)

90-3110 001 (IDENTIFICATION OF FRAGMENTS; CORTICOSTEROIDS INCREASE LIPOCORTIN-I; RAS ADENYLATE-CYCLASE PATHWAY; HEAT-SHOCK PROTEIN HSP70 FAMILY)

Cited References:

ANDERSON NE, 1988, V24, P559, ANN NEUROL
ANGST BD, 1990, V97, P247, J CELL SCI
ANHALT GJ, 1990, V323, P1729, NEW ENGL J MED
BRASHEAR HR, 1989, V39, P1605, NEUROLOGY
CASTLEMAN B, 1954, V250, P26, NEW ENGL J MED
COWIN P, 1986, V46, P1063, CELL
ERLANDSON RA, 1981, P107, DIAGNOSTIC TRANSMISS
FRANKE WW, 1981, V20, P217, DIFFERENTIATION
FRANKE WW, 1983, V23, P115, DIFFERENTIATION
FURNEAUX HM, 1990, V322, P1844, NEW ENGL J MED
GEIGER B, 1983, V23, P189, DIFFERENTIATION
GHADIALLY FN, 1982, P1, ULTRASTRUCT PATHOL
GREEN KJ, 1990, V265, P2603, J BIOL CHEM
GREEN KJ, 1988, V85, P2613, P NATL ACAD SCI USA
GREENLEE JE, 1986, V19, P82, ANN NEUROL
GREENLEE JE, 1988, V47, P561, J NEUROPATHOL EXP NE
GRUNWALD GB, 1987, V60, P780, CANCER
GRUNWALD GB, 1985, V1, P658, LANCET
KORMAN NJ, 1989, V321, P631, NEW ENGL J MED
KORNGUTH SE, 1982, V245, P35, BRAIN RES
KORNGUTH SE, 1982, V50, P1289, CANCER
KORNGUTH SE, 1986, V46, P2588, CANCER RES
LABIB RS, 1986, V136, P1231, J IMMUNOL
MA ASP, 1988, V90, P331, J INVEST DERMATOL
MIETTINEN M, 1991, V138, P505, AM J PATHOL
NELVILLE DM, 1971, V246, P6328, J BIOL CHEM
OKEEFE EJ, 1989, V264, P8310, J BIOL CHEM
OKEEFE EJ, 1989, V264, P8310, J BIOL CHEM
RODRIGUEZ M, 1988, V38, P1380, NEUROLOGY
SCHLAKE HP, 1989, V91, P329, CLIN NEUROL NEUROSUR
SCHWARZ MA, 1990, V6, P461, ANNU REV CELL BIOL
SMITH JL, 1988, V18, P37, J NEUROIMMUNOL
STANLEY JR, 1982, V70, P281, J CLIN INVEST
STANLEY JR, 1984, V74, P313, J CLIN INVEST
STANLEY JR, 1989, V83, P1443, J CLIN INVEST
THIRKILL CE, 1989, V321, P1567, NEW ENGL J MED
TOWBIN H, 1979, V76, P4350, P NATIONAL ACADEMY S
TSUKAMOTO T, 1989, V46, P1225, ARCH NEUROL-CHICAGO

3/9/17 (Item 6 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

01736539 Genuine Article#: HX169 Number of References: 55
Title: DNA TOPOISOMERASE-I PHOSPHORYLATION IN MURINE FIBROBLASTS TREATED WITH 12-O-TETRADECANOYLPHORBOL-13-ACETATE AND INVITRO BY PROTEIN-KINASE-C
Author(s): SAMUELS DS; SHIMIZU N
Corporate Source: NIAID,VECTORS & PATHOGENS LAB,ROCKY MT LABS/HAMILTON//MT/59840; UNIV ARIZONA,DEPT MOLEC & CELLULAR BIOL/TUCSON//AZ/85721; KEIO UNIV,SCH MED,DEPT MOLEC BIOL,SHINJUKU KU/TOKYO 160//JAPAN/
Journal: JOURNAL OF BIOLOGICAL CHEMISTRY, 1992, V267, N16 (JUN 5), P 11156-11162
Language: ENGLISH Document Type: ARTICLE
Geographic Location: USA; JAPAN
Subfile: SciSearch; CC LIFE--Current Contents, Life Sciences
Journal Subject Category: BIOCHEMISTRY & MOLECULAR BIOLOGY
Abstract: The phosphorylation of DNA topoisomerase I in quiescent murine 3T3-L1 fibroblasts treated with the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) was characterized by in vivo labeling with [P-32] orthophosphate and immunoprecipitation with a scleroderma anti-DNA topoisomerase I autoantibody. DNA topoisomerase I phosphorylation was stimulated 4-fold by 2 h of TPA treatment (TPA at 100 ng/ml maximally enhanced phosphorylation). Purified DNA topoisomerase I was phosphorylated in vitro in a Ca2+ and phospholipid-dependent fashion by types I, II, and III protein kinase C. The phosphorylation reaction was stimulated by TPA and had an apparent K(m) of·0.4-mu-M. DNA topoisomerase I was phosphorylated in vivo and in vitro predominantly at serine. The major tryptic phosphopeptides from DNA topoisomerase I in TPA-treated fibroblasts and phosphorylated by protein kinase C comigrated in thin-layer electrophoresis. The half-life of incorporated phosphate on DNA topoisomerase I was 40 min in both TPA-treated and control cells. These results suggest that phosphorylation is a mechanism for activating DNA topoisomerase I in fibroblasts treated with TPA and that protein kinase C functions in the phosphorylation.
Identifiers--KeyWords Plus: PROMOTING PHORBOL ESTERS; SCLERODERMA PATIENTS; SIGNAL-TRANSDUCTION; GENETIC-EVIDENCE; TUMOR PROMOTERS; HEPATOMA-CELLS; NIH-3T3 CELLS; CALF THYMUS; LAMIN-B; ACTIVATION
Research Fronts: 90-2493 005 (PROTEIN KINASE-C; ONTOGENY OF PHORBOL ESTER RECEPTORS; SPHINGOSINE INCREASES INOSITOL TRISPHOSPHATE IN RAT PAROTID ACINAR-CELLS)
90-3960 002 (DNA TOPOISOMERASE-I; ANTITUMOR ANTIBIOTIC STREPTONIGRIN; POLY(ADENOSINE DIPHOSPHATE-RIBOSE) SYNTHESIS-DEFICIENT V79 CHINESE HAMSTER-CELL LINES)
90-0715 001 (ANTIBODY REPERTOIRE OF EARLY HUMAN B-CELLS; AUTOIMMUNE MICE; VK GENE FAMILIES; HEAVY-CHAIN VARIABLE REGIONS; SYSTEMIC LUPUS-ERYTHEMATOSUS; SOMATIC MUTATION)
90-0818 001 (BOMBESIN RECEPTOR; SWISS 3T3 CELLS; GASTRIN-RELEASING PEPTIDE)
90-3110 001 (IDENTIFICATION OF FRAGMENTS; CORTICOSTEROIDS INCREASE LIPOCORTIN-I; RAS ADENYLATE-CYCLASE PATHWAY; HEAT-SHOCK PROTEIN HSP70 FAMILY)
90-4275 001 (TRANSCRIPTION FACTOR CAMP RESPONSE ELEMENT-BINDING PROTEIN; CREB REGULATION; LEUCINE ZIPPER DOMAIN)
90-6763 001 (MOUSE GLIAL FIBRILLARY ACIDIC PROTEIN GENE; REGULATION OF TRANSCRIPTION FACTOR AP-2; PROMOTER REGION)
Cited References:

ACKERMAN P, 1988, V263, P2653, J BIOL CHEM
ACKERMAN P, 1985, V82, P3164, P NATL ACAD SCI USA
BAZZI MD, 1987, V26, P1974, BIOCHEMISTRY-US
BUTLER AP, 1986, V261, P9421, J BIOL CHEM
CASTAGNA M, 1982, V257, P7847, J BIOL CHEM
CODERONI S, 1990, V14, P35, MOL BIOL REP
DARPA P, 1988, V85, P2543, P NATL ACAD SCI USA
DURBAN E, 1983, V111, P897, BIOCHEM BIOPH RES CO
DURBAN E, 1985, V4, P2921, EMBO J
FERRO AM, 1983, V258, P6000, J BIOL CHEM
FIELDS AP, 1988, V263, P8253, J BIOL CHEM
GOLDBERG Y, 1988, V7, P2425, EMBO J
GONZALEZ GA, 1989, V337, P749, NATURE
GORSKY LD, 1989, V1, P83, CANCER COMMUN
GULDNER HH, 1986, V94, P132, CHROMOSOMA
HALSEY DL, 1987, V262, P2234, J BIOL CHEM
HECK MMS, 1989, V264, P5161, J BIOL CHEM
HECK MMS, 1988, V85, P1086, P NATL ACAD SCI USA
HORNBECK P, 1988, V85, P2279, P NATL ACAD SCI USA
HSIEH JC, 1991, V88, P9315, P NATL ACAD SCI USA
HUNTER T, 1980, V77, P1311, P NATL ACAD SCI USA
IMAGAWA M, 1987, V51, P251, CELL
JONGSTRABILEN J, 1983, V136, P391, EUR J BIOCHEM
KAISERMAN HB, 1988, V27, P3216, BIOCHEMISTRY-US
KIKKAWA U, 1983, V258, P1442, J BIOL CHEM
KORNBERG A, 1992, P395, DNA REPLICATION
KROLL DJ, 1991, V266, P7957, J BIOL CHEM
LAEMMLI UK, 1970, V227, P680, NATURE
LEACH KL, 1989, V109, P685, J CELL BIOL
LEACH KL, 1983, V80, P4208, P NATL ACAD SCI USA
LIU LF, 1990, V58, P351, ANN REV BIOCH
LIU LF, 1981, V78, P3487, P NATL ACAD SCI USA
MACFARLANE DE, 1986, V261, P6947, J BIOL CHEM
MAUL GG, 1986, V83, P5145, P NATL ACAD SCI USA
MILLS JS, 1982, V109, P1222, BIOCHEM BIOPH RES CO
NIEDEL JE, 1983, V80, P36, P NATL ACAD SCI USA
NISHIZUKA Y, 1984, V308, P693, NATURE
NISHIZUKA Y, 1988, V334, P661, NATURE
PATSKAN GJ, 1985, V45, P667, CANCER RES
POMMIER Y, 1990, V265, P9418, J BIOL CHEM
ROTTMANN M, 1987, V6, P3939, EMBO J
ROZENGURT E, 1986, V234, P161, SCIENCE
SAHYOUN N, 1986, V83, P1603, P NATL ACAD SCI USA
SAIJO M, 1990, V29, P583, BIOCHEMISTRY-US
SAMUELS DS, 1986, V209, P231, FEBS LETT
SAMUELS DS, 1989, V259, P57, FEBS LETT
SANDER M, 1984, V81, P6938, P NATL ACAD SCI USA
SHERO JH, 1986, V231, P737, SCIENCE
SHIMIZU Y, 1986, V46, P4027, CANCER RES
SHIMIZU Y, 1989, V15, P321, SOMAT CELL MOLEC GEN
TAN EM, 1982, V33, P167, ADV IMMUNOL
THOMAS TP, 1988, V48, P1910, CANCER RES
TSEDINH YC, 1984, V312, P785, NATURE
VOSBERG HP, 1985, V114, P19, CURR TOP MICROBIOL
WANG JC, 1987, V909, P1, BIOCHIM BIOPHYS ACTA

3/9/18 (Item 7 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

01726866 Genuine Article#: HW140 Number of References: 17
Title: RAPID ASSAY FOR IMMUNE-COMPLEX BOUND ANTIGENS FROM URINE OF CANCER-PATIENTS
Author(s): TAYLOR S; HUTH JF
Corporate Source: UNIV N CAROLINA,DEPT SURG,RM 168,BURNETT WOMACKBLDG,CB 7210/CHAPEL HILL//NC/27599
Journal: JOURNAL OF IMMUNOASSAY, 1992, V13, N2, P197-215
Language: ENGLISH Document Type: ARTICLE
Geographic Location: USA
Subfile: SciSearch; CC LIFE--Current Contents, Life Sciences
Journal Subject Category: IMMUNOLOGY
Abstract: Concentrated urine from patients with various types of cancer was fractionated by S-500 gel filtration chromatography to yield high molecular weight (mw) immune complexes (IC) and lower mw immunoglobulin (Ig) fractions. Column fractions were assayed for the presence of IgM and IgG by immunoblot probing using anti-human IgM and anti-human IgG alkaline phosphatase conjugates. These results were used to define IC fractions (those from high mw S-500 fractions which were positive for immunoglobulin) and Ig fractions (those from medium mw S-500 fractions which were Positive for immunoglobulin). Antigen components of high mw S-500 IC fractions were then determined by immunoblot probe using medium mw S-500 Ig fractions as the antibody probe (i.e. autoantibody). This method for identification of immune complex antigens has the potential to probe for tumor-associated antigens, autoantigens, or foreign antigens from starting material which contains both immune complex and free immunoglobulin.
Descriptors--Author Keywords: IMMUNE COMPLEX ; TUMOR-ASSOCIATED ANTIGEN ; AUTOANTIGEN ; IMMUNOBLOT ; URINARY ANTIGEN
Identifiers--KeyWords Plus: ELECTROPHORETIC TRANSFER; SARCOMA; PROTEINS
Research Fronts: 90-3110 002 (IDENTIFICATION OF FRAGMENTS; CORTICOSTEROIDS INCREASE LIPOCORTIN-I; RAS ADENYLATE-CYCLASE PATHWAY; HEAT-SHOCK PROTEIN HSP70 FAMILY)
Cited References:
VASTRA AROS TYCKERI, 1981, S451
GUPTA RK, 1988, V6, P81, DIS MARKERS
HUTH JF, 1981, V47, P2856, CANCER
HUTH JF, 1982, V49, P1150, CANCER
HUTH JF, 1984, V53, P1306, CANCER
HUTH JF, 1981, V65, P1037, CANCER TREAT REP
HUTH JF, 1987, V42, P591, J SURG RES
IMAI H, 1987, V103, P239, J IMMUNOL METHODS
INMAN RD, 1986, V63, P32, CLIN EXP IMMUNOL
LAEMMLI UK, 1970, V227, P680, NATURE
LLOYD KO, 1989, V49, P3362, CANCER RES
MERYHEW NL, 1989, V991, P470, BIOCHIM BIOPHYS ACTA
PHILLIPS TM, 1989, P289, MELANOMA ANTIGENS AN
QUEEN WD, 1989, V46, P14, ONCOLOGY
ROSSEN RD, 1977, V58, P1205, J NATL CANCER I
SINGHAL AK, 1987, V47, P5566, CANCER RES
TOWBIN H, 1979, V76, P4350, P NATIONAL ACADEMY S

3/9/19 (Item 8 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

01552582 Genuine Article#: HH749 Number of References: 53
Title: PRIMARY STRUCTURE OF NUMA, AN INTRANUCLEAR PROTEIN THAT DEFINES A NOVEL PATHWAY FOR SEGREGATION OF PROTEINS AT MITOSIS

Author(s): COMPTON DA; SZILAK I; CLEVELAND DW
Corporate Source: JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM/BALTIMORE//MD/21205
Journal: JOURNAL OF CELL BIOLOGY, 1992, V116, N6 (MAR), P1395-1408
Language: ENGLISH Document Type: ARTICLE
Geographic Location: USA
Subfile: SciSearch; CC LIFE--Current Contents, Life Sciences
Journal Subject Category: CYTOLOGY & HISTOLOGY
Abstract: From a collection of monoclonal antibodies that specifically bind to various parts of the mitotic apparatus in human cells (1991. J Cell Biol. 112:1083-1097), two (1F1 and 1H1) recognize a > 200-kD intranuclear protein that associates with the spindle immediately upon nuclear envelope breakdown and progresses down the spindle microtubules to concentrate ultimately at the pericentrosomal region. At the completion of anaphase this protein dissociates from the spindle microtubules and is imported into the regenerating nuclei through the nuclear pores. Overlapping cDNA clones that span the entire length of the corresponding 7.2-kb mRNA reveal an encoded polypeptide of 236,278 D that is predicted to contain two globular domains separated by a discontinuous alpha-helix with characteristics for adopting a coiled-coil structure. The corresponding gene is highly conserved but neither the DNA sequence nor the predicted amino acid sequence shows significant homology to any previously reported. Since the cDNA also encodes the epitopes recognized by antibodies specific for two previously described proteins, NuMA and centrophilin, and all three show similar molecular weights and localization during the cell cycle, NuMA, centrophilin, and the 1F1/1H1 antigen represent either the same protein or a family of proteins, for which the original name, NuMA, seems most appropriate. While the function of NuMA remains uncertain, its unusual pattern of segregation at mitosis defines a novel pathway for the segregation of nuclear proteins during cell division.
Identifiers--KeyWords Plus: MICROTUBULE-ASSOCIATED PROTEIN; MITOTIC APPARATUS PROTEIN; CELL-FREE SYSTEM; NEWT LUNG-CELLS; NUCLEAR-ENVELOPE; CHROMOSOME ATTACHMENT; SPINDLE; INHIBITION; INVITRO; AUTOANTIBODY
Research Fronts: 90-2362 003 (STA58 MAJOR ANTIGEN GENE; RHODOCOCCUS-FASCIANS CLONING VECTORS; ESCHERICHIA-COLI CHROMOSOME; PRECISE IDENTIFICATION)
90-1006 001 (PROTEIN FOLDING; SYNTHETIC PEPTIDES; HELIX COIL STABILITY-CONSTANTS FOR THE NATURALLY-OCCURRING AMINO-ACIDS)
90-3110 001 (IDENTIFICATION OF FRAGMENTS; CORTICOSTEROIDS INCREASE LIPOCORTIN-I; RAS ADENYLATE-CYCLASE PATHWAY; HEAT-SHOCK PROTEIN HSP70 FAMILY)
90-4925 001 (LOCALIZATION OF THE HEME-BINDING PROTEIN; NUCLEAR-PORE COMPLEX IN SACCHAROMYCES-CEREVISIAE; POLYPEPTIDE SEQUENCE; ESSENTIAL COMPONENT)
90-5674 001 (NUCLEAR ENVELOPES; RNA TRANSPORT INVITRO; PHOSPHORYLATION SITES IN LAMIN-A; CDC2 KINASE; EMBRYONAL CARCINOMA-CELLS; SURFACE OF MITOTIC CHROMOSOMES)
90-5893 001 (NUCLEAR LAMINA; INTERMEDIATE FILAMENT; MITOTIC CELLS; IF PROTEINS; PHOSPHORYLATION SITES; INHIBITION OF MITOSIS; MOUSE VIMENTIN)
90-6160 001 (BIOLOGICAL SEQUENCE DATABASE SEARCHES; MULTIGENE FAMILIES IN AFRICAN SWINE FEVER VIRUS; STRUCTURAL ORGANIZATION; MOLECULAR EVOLUTION; FUNCTIONAL DOMAINS)
Cited References:
ADAM SA, 1991, V66, P837, CELL
BENAVENTE R, 1989, V50, P209, EUR J CELL BIOL
BURKE B, 1986, V44, P639, CELL
CALARCOGILLAM PD, 1983, V35, P621, CELL
CHOU PY, 1974, V13, P222, BIOCHEMISTRY-US
CLEVELAND DW, 1983, V305, P738, NATURE

COMPTON DA, 1991, V112, P1083, J CELL BIOL
COOKE CA, 1990, V110, P1475, J CELL BIOL
FEINBERG AP, 1983, V132, P6, ANAL BIOCHEM
FINLAY DR, 1987, V104, P189, J CELL BIOL
GASSER SM, 1986, V188, P613, J MOL BIOL
GERACE L, 1988, V4, P335, ANN REV CELL BIOL
GERACE L, 1980, V19, P277, CELL
GLASS JR, 1990, V111, P1047, J CELL BIOL
GOLDFARB DS, 1986, V326, P641, NATURE
GORBSKY GJ, 1987, V104, P9, J CELL BIOL
HAYDEN JH, 1990, V111, P1039, J CELL BIOL
IZANT JG, 1982, V295, P248, NATURE
KALDERON D, 1984, V39, P499, CELL
KALLAJOKI M, 1991, V10, P3351, EMBO J
KOSHLAND DE, 1988, V331, P499, NATURE
LAEMMLI UK, 1970, V227, P680, NATURE
LANFORD RE, 1984, V37, P801, CELL
LANFORD RE, 1986, V8, P2722, MOL CELL BIOL
LOEWINGER L, 1988, V7, P2301, EMBO J
LOPATA MA, 1987, V105, P1707, J CELL BIOL
LYDERSEN BK, 1980, V22, P489, CELL
MAEKAWA T, 1991, V54, P255, EUR J CELL BIOL
MANIATIS T, 1982, MOL CLONING
MIAKELYE R, 1985, V41, P165, CELL
MITCHISON TJ, 1989, V1, P67, CURR OPINION CELL BI
NEWMEYER DD, 1988, V52, P641, CELL
NEWPORT JW, 1987, V56, P535, ANNU REV BIOCHEM
OTTAVIANO Y, 1985, V260, P624, J BIOL CHEM
PEPPER DA, 1984, V99, P503, J CELL BIOL
PFALLER R, 1991, V65, P209, CELL
PFARR CM, 1991, V345, P263, NATURE
PRICE CM, 1986, V166, P295, EXP CELL RES
REIMER G, 1987, V30, P793, ARTHRITIS RHEUM
RIEDER CL, 1991, V3, P59, CURR OPIN CELL BIOL
RIEDER CL, 1990, V110, P81, J CELL BIOL
ROBBINS J, 1991, V64, P615, CELL
SANGER F, 1977, V74, P5463, P NATL ACAD SCI USA
STEUER ER, 1991, V345, P266, NATURE
SULLIVAN KF, 1991, V100, P360, CHROMOSOMA
TOUSSON A, 1991, V112, P427, J CELL BIOL
VANNESS J, 1983, V171, P175, J MOL BIOL
VONKRIES JP, 1991, V64, P123, CELL
WILBUR WJ, 1983, V80, P726, P NATL ACAD SCI USA
YANG JT, 1989, V56, P879, CELL
YEN TJ, 1991, V10, P1245, EMBO J
YONEDA Y, 1987, V173, P586, EXP CELL RES
ZELIGS JD, 1979, V66, P53, J ULTRASTRUCT RES
?

Set	Items	Description
S1	0	(RAS (W) AUTOANTIBODY) AND (CANCER OR CARCINOMA OR TUMOR OR TUMUOR OR MALIGNANCY)
S2	21	(RAS AND AUTOANTIBODY) AND (CANCER OR CARCINOMA OR TUMOR OR TUMUOR OR MALIGNANCY)
S3	19	RD S2 (unique items)

?